JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan International Research Enhanced Equity ETF
JIRE
|
+$4.16B |
| 2 |
Microsoft
MSFT
|
+$2.29B |
| 3 |
Amazon
AMZN
|
+$2B |
| 4 |
UnitedHealth
UNH
|
+$1.76B |
| 5 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.42B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$4.61B |
| 2 |
Vanguard Short-Term Bond ETF
BSV
|
+$1.58B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$689M |
| 4 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$659M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.28% |
| 2 | Technology | 15.04% |
| 3 | Healthcare | 12.52% |
| 4 | Financials | 10.55% |
| 5 | Consumer Discretionary | 7.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4601
Franklin Covey
FC
$199M
| $314K | ﹤0.01% |
6,790
-2,870
| -30% | -$114K |
2016 Q1
25 quarters
|
|
4602
iShares iBonds Dec 2026 Term Corporate ETF
IBDR
$3.16B
| $314K | ﹤0.01% |
13,206
+8,706
| +193% | +$209K |
2020 Q1
9 quarters
|
|
|
TRUE
4603
DELISTED
TrueCar
TRUE
| $314K | ﹤0.01% |
121,488
-62,244
| -34% | -$206K |
2016 Q4
22 quarters
|
|
4604
Omega Flex
OFLX
$269M
| $313K | ﹤0.01% |
2,905
+1,402
| +93% | +$159K |
2017 Q4
18 quarters
|
|
4605
Teucrium Corn Fund
CORN
$138M
| $312K | ﹤0.01% |
12,414
-9,634
| -44% | -$275K |
2016 Q2
24 quarters
|
|
4606
Invesco FTSE RAFI Developed Markets ex-US ETF
PXF
$2.93B
| $312K | ﹤0.01% |
7,836
+2,471
| +46% | +$107K |
2022 Q1
1 quarter
|
|
4607
Advantage Solutions
ADV
$359M
| $311K | ﹤0.01% |
3,271
-105
| -3% | -$12.7K |
2020 Q1
9 quarters
|
|
4608
Nano X Imaging
NNOX
$51.9M
| $311K | ﹤0.01% |
27,450
+24,485
| +826% | +$255K |
2020 Q4
6 quarters
|
|
|
RPTX
4609
DELISTED
Repare Therapeutics
RPTX
| $311K | ﹤0.01% |
22,175
-2,864
| -11% | -$33.7K |
2020 Q4
6 quarters
|
|
|
DICE
4610
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $311K | ﹤0.01% |
19,990
+9,901
| +98% | +$170K |
2021 Q4
2 quarters
|
|
4611
DocGo
DCGO
$38.6M
| $310K | ﹤0.01% |
+43,411
| New | +$316K |
2022 Q2
0 quarters
|
|
4612
CALL
General Dynamics
GD
$89.2B
| $310K | ﹤0.01% |
+1,400
| New | +$322K |
2022 Q2
0 quarters
|
|
|
TBCP
4613
DELISTED
Thunder Bridge Capital Partners III Inc. Class A Common Stock
TBCP
| $309K | ﹤0.01% |
31,530
| – | – |
2022 Q1
1 quarter
|
|
4614
DoubleVerify
DV
$2.11B
| $307K | ﹤0.01% |
13,520
-3,116
| -19% | -$70.1K |
2021 Q2
4 quarters
|
|
|
ABGI
4615
DELISTED
ABG Acquisition Corp. I
ABGI
| $307K | ﹤0.01% |
+31,319
| New | +$307K |
2022 Q2
0 quarters
|
|
|
CORZ
4616
DELISTED
Core Scientific, Inc. Common Stock
CORZ
| $306K | ﹤0.01% |
205,561
+203,906
| +12,321% | +$937K |
2022 Q1
1 quarter
|
|
4617
Kinetik
KNTK
$4.2B
| $305K | ﹤0.01% |
8,930
-66,580
| -88% | -$2.47M |
2019 Q1
13 quarters
|
|
4618
Carter Bankshares
CARE
$711M
| $304K | ﹤0.01% |
23,101
-11,316
| -33% | -$174K |
2019 Q2
12 quarters
|
|
4619
Pennant Group
PNTG
$1.37B
| $304K | ﹤0.01% |
23,688
+5,206
| +28% | +$86.6K |
2019 Q4
10 quarters
|
|
4620
Relmada Therapeutics
RLMD
$394M
| $304K | ﹤0.01% |
15,976
+126
| +0.8% | +$2.75K |
2020 Q2
8 quarters
|
|
4621
CALL
TechnipFMC
FTI
$27B
| $303K | ﹤0.01% |
+45,000
| New | +$343K |
2022 Q2
0 quarters
|
|
4622
CS Disco
LAW
$275M
| $303K | ﹤0.01% |
16,855
-13,628
| -45% | -$351K |
2021 Q3
3 quarters
|
|
4623
Mitsubishi UFJ Financial
MUFG
$256B
| $303K | ﹤0.01% |
56,704
+3,684
| +7% | +$21.2K |
2013 Q2
36 quarters
|
|
4624
Cellebrite
CLBT
$2.81B
| $301K | ﹤0.01% |
58,892
+9,393
| +19% | +$48.9K |
2021 Q3
3 quarters
|
|
4625
Organogenesis Holdings
ORGO
$178M
| $301K | ﹤0.01% |
61,590
+10,777
| +21% | +$66.3K |
2019 Q1
13 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2022 Portfolio in Review
As of Q2 2022, JP Morgan Chase held 7,270 positions worth $718B, down 14% from $830B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q2 2022 filing shows 568 new, 2,561 increased, 2,728 reduced and 609 closed positions. Its largest new stake was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B. The largest sale was JPMorgan BetaBuilders Europe ETF, an estimated $4.61B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q2 2022 buy was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B.
- JP Morgan Chase added most to Microsoft in Q2 2022, an estimated $2.29B increase.
- JP Morgan Chase's biggest Q2 2022 reduction was JPMorgan BetaBuilders Europe ETF, cutting an estimated $4.61B.
- JP Morgan Chase fully exited Cerner Corp in Q2 2022, selling an estimated $608M.
- JP Morgan Chase's ten largest holdings make up 18% of its $718B portfolio in Q2 2022.
- JP Morgan Chase opened 568 new positions and closed 609 in Q2 2022.
- JP Morgan Chase's portfolio value fell 14% quarter-over-quarter to $718B.
Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.